SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cell Genesys, Inc. (Nasdaq:CEGE) today announced interim data from the ongoing Phase 1 clinical trial of GVAX immunotherapy for prostate cancer used in combination with ipilimumab in patients with advanced prostate cancer. Updated data reported includes median follow-up of approximately 22.3 months on the 12 patients enrolled in the escalation cohort of the trial and interim data on the 16 patients enrolled in the expansion cohort of the trial. These data were presented on Saturday, May 31, 2008, by Winald Gerritsen, M.D., Ph.D., director of the University Hospital Vrije Universiteit Cancer Center in Amsterdam, at the annual meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago, Illinois. GVAX immunotherapy for prostate cancer is an investigational product currently in development by Cell Genesys and ipilimumab is an investigational fully human anti-CTLA-4 antibody in development by Medarex, Inc. in partnership with Bristol-Myers Squibb Company.
